Search Within

Martin Henner Voss

  1. "2018"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (9)
Groups
  1. Department of Medicine (20)
  2. Genitourinary Oncology Service (20)
  3. Solid Tumor Oncology Division (20)
  4. Surgery (10)
  5. Human Oncology and Pathogenesis Program (9)
  6. Urology (9)

More Groups

People
  1. Robert Motzer (11)
  2. Abraham Hakimi (9)
  3. Chung-Han Lee (6)
  4. Maria Carlo (6)
  5. Darren Feldman (5)
  6. Almedina Djesevic (4)

More People

Years
  1. 2018 (20)
Publications
  1. Journal of Clinical Oncology (10)
  2. Journal for ImmunoTherapy of Cancer (3)
  3. Annals of Oncology (1)
  4. Cancer Cell (1)
  5. European Urology (1)
  6. European Urology Focus (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. Biomed Central Ltd (3)
  3. Elsevier Science, Inc. (2)
  4. American Association for the Advancement of Science (1)
  5. American Medical Association (1)
  6. Cell Press (1)

More Publishers

Results (20)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC)
    Meeting Abstract

    Voss, M. H.; Novik, J. B.; Hellmann, M. D.; Ball, M.; Hakimi, A. A.; Miao, D.; Margolis, C.; Horak, C.; Wind-Rotolo, M.; De Velasco, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Characterizing tumor immune microenvironment (TME) and outcomes for 409 patients (pts) treated on COMPARZ: Distinct clusters emphasize immune infiltration vs. angiogenesis
    Meeting Abstract

    Voss, M. H.; Kuo, F.; Sanchez, A.; Ostrovnaya, I.; Cheng, Y.; Patel, P.; Marker, M.; Reising, A.; Chan, T. A. T.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant
    Meeting Abstract

    Ged, Y.; Knezevic, A.; Chen, Y.; Redzematovic, A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis
    Meeting Abstract

    BosseĢ, D.; Xie, W.; Ged, Y.; Hahn, A. W.; Bergerot, P. G.; Ho, T. H.; McKay, R. R.; Rose, T. L.; de Velasco, G.; Tannir, N. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Cheng, Y.; Marker, M.; Kuo, F.; Choueiri, T. K.; Hsieh, J. J.; Reising, A.; Motzer, R. J.; Hakimi, A. A.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial
    Meeting Abstract

    Feldman, D. R.; Lee, C. H.; Molina, A. M.; Knezevic, A.; Chen, Y.; Chaim, J.; Coskey, D. T.; Ged, Y.; Tickoo, S.; Reuter, V. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes of metastatic chromophobe renal cell carcinoma (ChRCC) with sarcomatoid features (SF)
    Meeting Abstract

    Ged, Y.; Knezevic, A.; Chen, Y.; Redzematovic, A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma
    Meeting Abstract

    Bosse, D.; Xie, W.; Lalani, A. K. A.; de Velasco, G.; Voss, M. H.; Tannir, N. M.; Tamboli, P.; Appleman, L. J.; Rathmell, K.; Heng, D. Y. C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC)
    Meeting Abstract

    Cleary, J. M.; Voss, M. H.; Meric-Bernstam, F.; Hierro, C.; Heist, R. S.; Ishii, N.; Kirpicheva, Y.; Nicolas-Metral, V.; Pokorska-Bocci, A.; Vaslin, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Motzer, R. J.; Glen, H.; Michaelson, M. D.; Larkin, J.; Minoshima, Y.; Kanekiyo, M.; Dairiki, R.; Sachdev, P.; Dutcus, C. E.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save